Premium
Prognostic factors of alveolar rhabdomyosarcoma in childhood. An international society of pediatric oncology study
Author(s) -
ReboulMarty J.,
Mosseri V.,
Asselain B.,
Quintana E.,
Zucker J. M.,
Flamant F.,
Rodary C.
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910801)68:3<493::aid-cncr2820680308>3.0.co;2-#
Subject(s) - medicine , rhabdomyosarcoma , alveolar rhabdomyosarcoma , pediatric oncology , oncology , pediatrics , pathology , cancer , sarcoma
Pretreatment characteristics of 57 patients with alveolar rhabdomyosarcoma (RMS) registered by the International Society of Pediatric Oncology (SIOP) between January 1975 and December 1983 were identified to perform a prognostic factor study. Living status and disease‐free survival (DFS) time were assessed for all patients on January 1, 1988. By multi‐variate analyses, lymph node involvement ( P = 0.0003) and tumor invasiveness ( P = 0.007) were identified as the most significant covariates correlated with survival. A model including N stage ( P = 0.001) and age ( P = 0.03) was selected for predicting DFS rates. Children between 5 and 10 years of age had better DFS rates than those younger than 5 years of age or those older than 10 years of age. The authors suggest a prognostic classification that could allow treatment to be adjusted according to clinical staging.